Dupilumab after a severe COPD flare-up
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests whether adding the drug dupilumab to usual hospital care for a severe COPD flare-up helps patients recover better than usual care alone. It is for adults with a specific type of inflammation in their blood, and may reduce the chance of future flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a doctor's diagnosis of COPD (chronic lung disease).
- You must be in the hospital (or ER for over a day) for a sudden COPD flare-up that was treated with steroids, possibly with antibiotics.
- Your blood test during this flare-up must show a high level of eosinophils, which are a type of white blood cell linked to lung inflammation.
- You cannot have pneumonia as the main reason for being admitted.
- You cannot need a ventilator (breathing machine) during this hospital stay.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well dupilumab works over time for people with COPD who still have symptoms despite standard treatments and who have a certain type of inflammation (elevated eosinophils). It uses data from regular doctor visits and patient questionnaires to understand real-world benefits and safety.
This study looks at how well dupilumab works for people with uncontrolled COPD who have high levels of a certain white blood cell (eosinophils). It collects information from routine doctor visits to see how patients feel and if the treatment is safe.
This study tests if a drug called dupilumab, given as a shot under the skin, can reduce airway inflammation in people aged 40-85 with moderate-to-severe COPD who also have signs of a specific type of inflammation called Type 2. It may help if you have frequent flare-ups and are already using multiple inhalers.
This is a registry—an observational study tracking patients with COPD (chronic lung disease) who are newly starting a medication called dupilumab. Researchers will follow your health outcomes to learn how well this treatment works in real-world practice.
This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.
This trial tests whether dupilumab, a medicine that helps reduce airway inflammation, can help people with asthma achieve remission. You may be eligible if you have asthma with high markers of inflammation and have had asthma attacks despite using your regular inhaler.
Hear when a new Chronic Obstructive Pulmonary Disease (COPD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.